Roberta Carosio

Roberta Carosio

Auto-generated profile, based on publicly available information

Roberta Carosio

Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2015 in Cell Cycle
Verified
Journal Article
Open access
BBBarbara Banelli
Barbara Banelli
ECElisa Carra
Elisa Carra
FBFederica Barbieri
Federica Barbieri
RWRoberto Würth
Roberto Würth
FPFederica Parodi
Federica Parodi
MRMassimo Romani
Massimo Romani
Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment. Therefore, understanding the mechanisms underlying chemoresistance is mandatory to improve treatments' outcome. We generated TMZ resistant cells (TMZ-R) from a GBM cell line and from cancer stem cell-enriched cultures isolated from human GBMs. We demonstrated that TMZ resistance is partially reverted by “drug wash-out” suggesting the contribution of epigenetic mechanisms in drug resistance and supporting the possibility of TMZ rechallenge in GBM patients after prior drug exposure. The expression of histone lysine demethylase genes (KDMs) was increased in TMZ-R cells compared to parental cells, and TMZ resistance or restored sensitivity was mimicked by over-expressing or inactivating KDM5A. Methylation and expression of O6-methylguanine-DNA methyltransferase (MGMT) and drug efflux mechanisms were not altered in TMZ-R cells compared to parental TMZ sensitive cells. TMZ-R cells transiently acquired morphologic and molecular characteristics of differentiated tumor cells, features that were lost after drug wash-out. In conclusion, we demonstrated that treatment-induced TMZ resistance in GBM involves epigenetic mechanisms in a subset of slow-cycling and transiently partially differentiated cells that escape drug cytotoxicity, overcome G2 checkpoint and sustain clonal growth. We found that TMZ-R cells are sensitive to histone deacethylase inhibitors (HDACi) that synergize with TMZ. This strong synergism could be exploited to develop novel combined adjuvant therapies for this rapidly progressing and invariably lethal cancer.

15 March 2004 in Blood
Verified
Journal Article
Closed access
PDF file
Alessandro PoggiAlessandro Poggi
Alessandro Poggi
RCRoberta Carosio
Roberta Carosio
DFDaniela Fenoglio
Daniela Fenoglio
SBSabrina Brenci
Sabrina Brenci
GMGiuseppe Murdaca
Giuseppe Murdaca
MZMaria Raffaella Zocchi
Maria Raffaella Zocchi
We show that HIV-1–infected patients have increased concentrations of circulating Vδ1 T cells (2.2%-9.0% of T lymphocytes; healthy donors, 1.0%-2%) and, in some instances, Vδ2 T cells (3.5%-4.8% vs 2.0%-3.3%). In these patients, both Vδ1 and Vδ2 T cells are CXCR3+CXCR4+, whereas in healthy donors CXCR4 was preferentially expressed on Vδ1 T lymphocytes. γδ T cells transmigrated across endothelial monolayers, in response to interferon-γ–inducing protein-10 (IP-10/CXCL10), stromal cell–derived factor-1 (SDF-1/CXCL12), or both, according to the expression of the specific receptors CXCR3 and CXCR4. Interestingly, 6Ckine/SLC/CCL21 was more effective than IP-10/CXCL10 on Vδ1 CXCR3+ cells, whereas Vδ2 CXCR3+ cells were driven more efficiently by IP-10/CXCL10. IP-10/CXCL10– and SDF-1/CXCL12–induced transmigration was dependent on phosphoinositide-3 kinase (PI-3K), as demonstrated by the use of the specific blockers wortmannin and LY294002 and by the activation of the downstream serine kinase Akt/PKB on ligation of CXCR3 and CXCR4. Occupancy of CXCR3, but not of CXCR4, led to CAMKII activation; accordingly, the CAMKII inhibitors KN62 and KN93 decreased IP-10/CXCL10– but not SDF-1/CXCL12–driven transmigration. Finally, HIV-1 Tat, which is present in the serum of HIV-1–infected patients, interferes with the chemotactic activity of these chemokines because of the cysteine-rich domain of the protein, which contains CXC and CC chemokine–like sequences.

1 June 2001 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GSGrazia Maria Spaggiari
Grazia Maria Spaggiari
RCRoberta Carosio
Roberta Carosio
DPDaniela Pende
Daniela Pende
SMStefania Marcenaro
Stefania Marcenaro
PRPaola Rivera
Paola Rivera
Alessandro PoggiAlessandro Poggi
Alessandro Poggi

1 December 2002 in Blood
Verified
Journal Article
Closed access
PDF file
GSGrazia Maria Spaggiari
Grazia Maria Spaggiari
PCPaola Contini
Paola Contini
ADAlessandra Dondero
Alessandra Dondero
RCRoberta Carosio
Roberta Carosio
FPFrancesco Puppo
Francesco Puppo
Alessandro PoggiAlessandro Poggi
Alessandro Poggi
The engagement of the activating isoforms of C-type lectin inhibitory receptor (CLIR) or killer Ig-like receptor (KIR) by their natural ligands, represented by soluble HLA-I (sHLA-I) molecules, induced programmed cell death of natural killer (NK) cells. Indeed, NK cell apoptosis elicited by either putative HLA-E and HLA-F (sHLA-I non-A, -B, -C, and -G) or sHLA-I–Cw4 or –Cw3 from untransfected or –Cw4 or –Cw3 alleles transfected HLA-A−, B−, C−, G−, E+, F+ 721.221 lymphoblastoid cell line, respectively, was blocked by covering the corresponding activating receptor with either anti-CLIR– or anti-KIR–specific monoclonal antibodies (mAbs). After sHLA-I–activating receptor interaction, NK cells produced and released Fas ligand (FasL), which in turn led to NK cell apoptosis by interacting with Fas at the NK cell surface. Blocking anti-Fas mAb, or anti-FasL mAb, inhibited sHLA-I–mediated apoptosis via activating receptor in NK cell clones. This apoptosis was inhibited by NK cell treatment with cyclosporin A, whereas this drug had no effect on activating receptor–mediated activation of cytolysis. Conversely, concanamycin A, an inhibitor of vacuolar type H+–adenosine triphosphatase (H+-ATPase) of granules, inhibited activating receptor–induced NK cell cytolysis, suggesting that activating receptor–mediated apoptosis and cytolysis can use different intracellular pathways. Furthermore, a large amount of interferon-γ (IFN-γ) was detectable in culture supernatant of activating receptor+ NK cells incubated with the appropriate sHLA-I ligand. Again, cyclosporin A, but not concanamycin A, strongly reduced activating receptor–mediated IFN-γ production. This suggests that activating receptor–induced apoptosis of NK cells could play a role in eliminating potentially harmful NK cell clones and, at the same time, it leads to production of IFN-γ, an antiviral cytokine able to amplify immune responses.

11 October 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
I(Italian Melanoma Intergroup On behalf of the Italian Melanoma Intergroup (IMI)
Italian Melanoma Intergroup On behalf of the Italian Melanoma Intergroup (IMI)
MPMaria Pia Pistillo
Maria Pia Pistillo
VFVincenzo Fontana
Vincenzo Fontana
AMAnna Morabito
Anna Morabito
BDBeatrice Dozin
Beatrice Dozin
PQPaola Queirolo
Paola Queirolo

23 October 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MRMassimo Romani
Massimo Romani
MPMaria Pia Pistillo
Maria Pia Pistillo
RCRoberta Carosio
Roberta Carosio
AMAnna Morabito
Anna Morabito
BBBarbara Banelli
Barbara Banelli
Targeting the Immune Checkpoint molecules (ICs; CTLA-4, PD-1, PD-L1/2 and others) which provide inhibitory signals to T cells, dramatically improves survival in hard-to-treat tumors. The establishment of an immunosuppressive environment prevents endogenous immune response in glioblastoma; therefore, manipulating the host immune system seems a reasonable strategy also for this tumor. In glioma patients the accumulation of CD4+/CD8+ T cells and Treg expressing high levels of CTLA-4 and PD-1, or the high expression of PD-L1 in glioma cells correlates with WHO high grade and short survival. Few clinical studies with ICis were completed so far. Notably, the first large-scale randomized trial (NCT 02017717) that compared PD-1 blockade and anti-VEGF, did not show an OS increase in the patients treated with anti-PD-1. Several factors could have contributed to the failure of this trial and must be considered to design further clinical studies. In particular the possibility of targeting at the same time different ICs was preclinically tested in an animal model were inhibitors against IDO, CTLA-4 and PD-L1 were combined and showed persistent and significant antitumor effects in glioma-bearing mice. It is reasonable to hypothesize that the immunological characterization of the tumor in terms of type and level of expressed IC molecules on the tumor and TIL may be useful to design the optimal ICi combination for a given subset of tumor to overcome the immunosuppressive milieu of glioblastoma and to efficiently target a tumor with such high cellular complexity.